Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: The immunomodulatory drugs thalidomide and lenalidomide recently received US Food and Drug Administration approval for the treatment of multiple myeloma.1- 4 Venous thromboembolism (VTE) is a potentially serious complication associated with their use.5- 8 We conducted a systematic review of thromboembolism occurring with immunomodulatory drug treatment of cancer.
Bennett CL, Angelotta C, Yarnold PR, Evens AM, Zonder JA, Raisch DW, Richardson P. Thalidomide- and Lenalidomide-Associated Thromboembolism Among Patients With Cancer. JAMA. 2006;296(21):2555-2560. doi:10.1001/jama.296.21.2558-c